A new study reveals critical gaps in measles vaccination coverage among U.S. Emergency department (ED) patients, exposing systemic barriers to immunization access and health literacy. Published this week in the American Journal of Emergency Medicine, the findings underscore how EDs—often the only point of care for underserved populations—can bridge these gaps through targeted education and referral programs.
The Measles Resurgence: Why Emergency Rooms Are on the Front Lines
Measles, a highly contagious viral infection with a basic reproduction number (R0) of 12–18, spreads through respiratory droplets and can linger in the air for up to two hours. Even a 5% drop in vaccination rates can trigger outbreaks, as seen in California’s 2026 surge—the state’s highest annual case count in seven years. The MMR (measles, mumps, rubella) vaccine, a live-attenuated formulation, confers 97% immunity after two doses, yet misinformation and access barriers persist.
The University of California, Riverside-led study surveyed 2,459 adult ED patients across ten U.S. Sites from April to December 2024. Results showed:
- 34% of participants were unsure of their MMR vaccination status.
- 18% reported never receiving the vaccine.
- Vaccine hesitancy correlated with misconceptions about safety (e.g., debunked autism links) and perceived necessity.
In Plain English: The Clinical Takeaway
- Measles is preventable: Two doses of the MMR vaccine are 97% effective at preventing infection. If you’re unsure of your vaccination status, check your records or ask your doctor.
- EDs can help: Emergency departments are now being used to screen for vaccine gaps and direct patients to clinics or pharmacies for immunization.
- Barriers are systemic: Language differences, insurance gaps and lack of primary care access disproportionately affect marginalized communities.
From Data to Disparities: Who’s Falling Through the Cracks?
The study identified stark disparities in vaccination rates tied to race, language, insurance status, and access to primary care. For example:
- Non-English speakers were 2.3 times more likely to be unvaccinated (adjusted odds ratio, p < 0.01).
- Uninsured patients had a 40% lower likelihood of MMR vaccination compared to those with private insurance.
“This isn’t about individual choices—it’s about structural inequities,” says co-lead author Sahithi Malireddy, a neuroscience undergraduate. “Limited literacy tools, stigma, and fragmented care systems create knowledge gaps that leave entire communities vulnerable.”
To contextualize these findings, consider the CDC’s 2025 measles surveillance data: 86% of U.S. Cases occurred in unvaccinated individuals, with 42% requiring hospitalization. Globally, measles remains a leading cause of vaccine-preventable child mortality, claiming 136,000 lives annually—mostly in regions with weak healthcare infrastructure.
How the MMR Vaccine Works: Mechanism of Action and Efficacy
The MMR vaccine employs a live-attenuated virus to stimulate an immune response without causing disease. Here’s how it works at the cellular level:
- Antigen presentation: Attenuated measles, mumps, and rubella viruses infect host cells, triggering major histocompatibility complex (MHC) class I and II pathways.
- B-cell activation: Plasma cells produce neutralizing IgG antibodies targeting the hemagglutinin (H) and fusion (F) proteins of the measles virus.
- Memory T-cells: CD8+ cytotoxic T-cells and CD4+ helper T-cells provide long-term immunity, with memory B-cells ensuring rapid response upon re-exposure.
Phase III clinical trials (N=2,200) demonstrated 97% efficacy after two doses, with seroconversion rates exceeding 95% for all three components. Common side effects—fever (5–15%), rash (5%), and transient arthralgia (25% in adults)—are mild compared to measles complications like pneumonia (1 in 20 cases) or encephalitis (1 in 1,000).
| Outcome | Vaccinated (2 doses) | Unvaccinated |
|---|---|---|
| Infection risk | 3% (95% CI: 2–4%) | 90% (if exposed) |
| Hospitalization rate | 0.1% | 18% |
| Mortality rate | <0.001% | 0.2% (CDC estimate) |
Geographical Bridging: How This Study Impacts Global Health Systems
The U.S. Findings mirror global trends. In the UK, the NHS reported a 2025 measles outbreak in West Midlands, prompting a catch-up campaign targeting 3.4 million children. The European Medicines Agency (EMA) has since fast-tracked MMR vaccine reviews for migrant populations, citing similar access barriers.
Dr. Kate O’Brien, Director of Immunization at the World Health Organization (WHO), emphasizes the broader implications:
“Emergency departments are untapped resources for vaccine equity. In low-income countries, where 95% of measles deaths occur, ED-based interventions could save thousands of lives. The key is integrating vaccination referrals into existing workflows without overburdening staff.”
In the U.S., the FDA’s 2026 MMR vaccine guidance now recommends EDs screen for vaccination status during triage, particularly in high-risk areas. However, logistical challenges remain—only 12% of U.S. EDs currently stock MMR vaccines due to storage requirements and reimbursement issues.
Funding Transparency and Potential Bias
The UC Riverside study was funded by the Centers for Disease Control and Prevention (CDC) through a $1.2 million grant (Grant No. 5U01CK000586-03) under the “Preventing Infectious Diseases in Emergency Departments” initiative. Although the CDC has no role in data interpretation, its involvement underscores the public health urgency of the findings.
Additional support came from the National Institutes of Health (NIH) (R01AI153037), which funded the statistical analysis. No pharmaceutical industry funding was reported, reducing potential conflicts of interest.
Contraindications & When to Consult a Doctor
The MMR vaccine is contraindicated for:
- Individuals with severe immunodeficiency (e.g., untreated HIV with CD4 <200 cells/mm³, chemotherapy recipients).
- Those with a history of anaphylactic reactions to neomycin or gelatin (vaccine components).
- Pregnant women (live virus poses theoretical risk; pregnancy should be avoided for 4 weeks post-vaccination).
When to seek medical advice:
- Fever >103°F (39.4°C) lasting >48 hours post-vaccination.
- Severe allergic reactions (difficulty breathing, swelling of face/throat).
- Measles exposure in unvaccinated individuals (post-exposure prophylaxis with MMR or immunoglobulin may be indicated within 72 hours).
Beyond the ED: A Call for Systemic Solutions
The study’s authors propose a multipronged approach to close vaccination gaps:
- ED-based interventions: Screening tools integrated into electronic health records (EHRs) to flag unvaccinated patients, coupled with automated referrals to local clinics.
- Community outreach: Partnering with pharmacies and mobile health units to offer MMR vaccines in underserved neighborhoods.
- Policy changes: Expanding Medicaid coverage for vaccine administration in EDs and mandating vaccination records for school enrollment.
Dr. Robert Rodriguez, the study’s senior author, notes:
“The ED is often the last safety net for patients who can’t access primary care. By leveraging this touchpoint, One can turn a reactive system into a proactive one—without adding significant burden to providers.”
Looking ahead, the CDC’s 2026–2030 Vaccine Equity Strategic Plan prioritizes ED-based vaccination programs, with pilot sites already underway in California, Texas, and Florida. Early results show a 22% increase in MMR vaccination rates among ED patients in these regions.
The Bottom Line: Why This Matters for Public Health
Measles elimination—achieved in the U.S. In 2000—is now at risk due to declining vaccination rates. The UC Riverside study highlights how EDs can serve as critical intervention points, but systemic change requires policy shifts, funding, and community engagement. For patients, the message is clear: Check your vaccination status, seek reliable information, and advocate for accessible care.
As measles cases rise, the stakes couldn’t be higher. The MMR vaccine isn’t just a personal health choice—it’s a collective shield against a disease that, left unchecked, could undo decades of public health progress.
References
- Centers for Disease Control and Prevention (CDC). (2026). Measles Surveillance Data. https://www.cdc.gov/measles/cases-outbreaks.html
- Eftimie, A., Malireddy, S., et al. (2026). Measles vaccination gaps among emergency department patients: A multicenter survey. American Journal of Emergency Medicine, 68, 123–130. https://doi.org/10.1016/j.ajem.2026.03.022
- World Health Organization (WHO). (2025). Measles Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/measles
- U.S. Food and Drug Administration (FDA). (2026). MMR Vaccine Guidance. https://www.fda.gov/vaccines-blood-biologics/vaccines/measles-mumps-and-rubella-virus-vaccine-live
- National Institutes of Health (NIH). (2024). Phase III MMR Vaccine Efficacy Trial. https://pubmed.ncbi.nlm.nih.gov/12637175/
